Form 4: Clene CFO Morgan Brown Granted 35,000 Stock Options

Clene Inc.'s Chief Financial Officer, Morgan R. Brown, was granted 35,000 stock options with an exercise price of $5.42 per share, vesting immediately.

Summary

• Morgan R. Brown, Chief Financial Officer of Clene Inc. (CLNN), was granted 35,000 stock options.
• The options were granted on January 22, 2026, under the Clene Inc. Amended 2020 Stock Plan.
• The exercise price for these options is $5.42 per share.
• The options vest immediately upon grant, making them exercisable as of January 22, 2026.
• The expiration date for these options is January 21, 2036.
• Following this transaction, Mr. Brown beneficially owns 35,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is generally viewed as a neutral to slightly positive event, as it aligns management's interests with shareholders and incentivizes performance. It is a standard compensation practice.

Positives

• The grant of stock options aligns the Chief Financial Officer's interests with those of shareholders, incentivizing long-term company performance.
• Immediate vesting provides direct ownership and motivation for the executive.

Negatives

• Potential for future dilution if the options are exercised and new shares are issued, though this is a standard aspect of stock-based compensation.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

The grant of stock options to executive officers is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract, retain, and incentivize key talent by linking their compensation to the company's stock performance.

Comparison to Industry Standards

• The grant of stock options to a Chief Financial Officer is a standard component of executive compensation packages across various industries, including biotechnology.
• While the specific number of options (35,000) and exercise price ($5.42) are company-specific, the mechanism of using stock options to align executive incentives with shareholder value is a widely adopted practice, similar to compensation structures seen at companies like Biogen or Amgen, where executive compensation often includes a significant equity component.

Related Party Transactions

• This transaction represents a direct grant of compensation to an officer, which is a related party transaction, executed under an approved stock plan.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also increased alignment of management's interests with shareholder value.
• Employees (CFO): Provides a significant incentive and compensation component tied to company performance.

Next Steps

• The Chief Financial Officer may choose to exercise these options at any time between the vesting date (January 22, 2026) and the expiration date (January 21, 2036), provided the stock price is above the exercise price.

Key Dates

Keywords

Clene Inc., CLNN, Morgan R. Brown, Chief Financial Officer, CFO, stock options, executive compensation, insider transaction, Form 4, equity grant, beneficial ownership